Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):38-44. doi: 10.1016/j.ijrobp.2018.09.005. Epub 2018 Sep 10.
For pediatric patients with large, high-grade, extremity nonrhabdomyosarcoma soft-tissue sarcomas, preoperative radiation therapy (RT) provides the opportunity for smaller radiation fields and tumor shrinkage resulting in less extensive surgery. The potential disadvantage is an increased risk of wound complications after surgery compared with rates after postoperative chemoradiation. We assessed the impact of preoperative RT technique on target coverage in relationship to dose to skin and adjacent joints to determine whether acute wound complications and late musculoskeletal injury might be influenced by treatment technique.
Of 550 eligible patients <30 years of age, 200 were enrolled in arm D of ARST0332 and received neoadjuvant ifosfamide/doxorubicin, then chemoradiotherapy (45 Gy and ifosfamide) and surgery followed by postoperative RT if gross or microscopic positive surgical margins. One-hundred thirteen patients had extremity nonrhabdomyosarcoma soft-tissue sarcomas, of which 56 patients had preoperative RT plans for digital review. The doses to the target volume, skin (surface to 5 mm depth), adjacent joint, and extremity diameter were analyzed with respect to RT technique.
Thirty-eight patients (65%) received 3-dimensional conformal RT (3D-CRT) and 18 (32%) received intensity modulated RT (IMRT). There was no difference in clinical target volume (CTV) size between groups (P = .920); however, IMRT plans had improved CTV coverage to 100% of the prescription dose compared with 3D-CRT plans (median CTV coverage, 92.7% vs 98.6%; P = .011). In patients without target overlap with the skin, IMRT use was associated with reduced percent volume of skin receiving 45 Gy or more (V45Gy) compared with 3D-CRT (median, 1.6% vs 6.3%, respectively; P = .005). IMRT was also associated with reduced V45Gy to the adjacent joint compared with 3D-CRT (median, 1.1% vs 13.2%; P = .018).
Preoperative IMRT may improve CTV coverage and reduce the volume of skin and adjacent joint treated to high doses. Future studies should assess whether these dosimetric findings produce differences in clinical and toxicity outcomes.
对于患有大体积、高级别、肢体非横纹肌肉瘤软组织肉瘤的儿科患者,术前放疗(RT)提供了使用较小辐射野和肿瘤缩小的机会,从而减少了广泛的手术。潜在的缺点是与术后放化疗后相比,手术后伤口并发症的风险增加。我们评估了术前 RT 技术对目标覆盖范围的影响,以及对皮肤和相邻关节剂量的影响,以确定急性伤口并发症和晚期肌肉骨骼损伤是否可能受到治疗技术的影响。
在 550 名符合条件的<30 岁患者中,200 名患者入组 ARST0332 的 D 臂,接受新辅助异环磷酰胺/多柔比星,然后接受化疗和放疗(45 Gy 和异环磷酰胺),如果肿瘤切缘阳性则行手术,然后行术后放疗。113 例患者患有肢体非横纹肌肉瘤软组织肉瘤,其中 56 例患者有术前 RT 计划供数字复查。分析了与 RT 技术相关的靶体积、皮肤(表面至 5mm 深度)、相邻关节和肢体直径的剂量。
38 例(65%)患者接受 3 维适形放疗(3D-CRT),18 例(32%)患者接受调强放疗(IMRT)。两组患者的临床靶体积(CTV)大小无差异(P=0.920);然而,与 3D-CRT 相比,IMRT 计划显著提高了 CTV 至 100%处方剂量的覆盖(CTV 覆盖中位数,92.7%对 98.6%;P=0.011)。在没有与皮肤重叠的靶区的患者中,与 3D-CRT 相比,IMRT 可降低皮肤 45Gy 或更高剂量的体积百分比(V45Gy)(中位数,1.6%对 6.3%;P=0.005)。与 3D-CRT 相比,IMRT 还可降低相邻关节的 V45Gy(中位数,1.1%对 13.2%;P=0.018)。
术前 IMRT 可能提高 CTV 覆盖范围,降低皮肤和相邻关节的高剂量体积。未来的研究应评估这些剂量学发现是否会导致临床和毒性结果的差异。